Vistara facilitates early diagnosis for single-gene disorders

Vistara facilitates early diagnosis for single-gene disorders

Vistara facilitates early diagnosis for single-gene disorders

Vistara facilitates early diagnosis for single-gene disorders

Vistara is a non-invasive prenatal test (NIPT) that screens for single-gene mutations in cell-free fetal (placental) DNA

Vistara screens for severe conditions across 30 genes that affect the skeletal, cardiac, and neurological systems

Conditions screened through Vistara have a combined incidence of 1 in 600, higher than that of Down syndrome. The conditions screened meet at least one of the following criteria:

  • Cause cognitive disability
  • Require surgical or medical intervention
  • Affect quality of life

SEE ALL CONDITIONS

Vistara screens for severe conditions across 30 genes that affect the skeletal, cardiac, and neurological systems

Conditions screened through Vistara have a combined incidence of 1 in 600, higher than that of Down syndrome. The conditions screened meet at least one of the following criteria:

  • Cause cognitive disability
  • Require surgical or medical intervention
  • Affect quality of life

SEE ALL CONDITIONS

Vistara screens for severe conditions across 30 genes that affect the skeletal, cardiac, and neurological systems

Conditions screened through Vistara have a combined incidence of 1 in 600, higher than that of Down syndrome. The conditions screened meet at least one of the following criteria:

  • Cause cognitive disability
  • Require surgical or medical intervention
  • Affect quality of life

SEE ALL CONDITIONS

Vistara screens for severe conditions across 30 genes that affect the skeletal, cardiac, and neurological systems

Conditions screened through Vistara have a combined incidence of 1 in 600, higher than that of Down syndrome. The conditions screened meet at least one of the following criteria:

  • Cause cognitive disability
  • Require surgical or medical intervention
  • Affect quality of life

SEE ALL CONDITIONS

Vistara has a combined analytical sensitivity of >99% and a combined analytical specificity of >99% in validation studies

Vistara has a combined analytical sensitivity of >99% and a combined analytical specificity of >99% in validation studies

Vistara has a combined analytical sensitivity of >99% and a combined analytical specificity of >99% in validation studies

Vistara has a combined analytical sensitivity of >99% and a combined analytical specificity of >99% in validation studies

Vistara can identify conditions that may have otherwise gone undetected until after birth or into childhood

  • Other NIPTs do not offer screening for these conditions, and invasive testing does not guarantee a diagnosis
  • Family histories are typically not good indicators of risk for these conditions, which are commonly caused by de novo, or new, mutations
  • Ultrasound findings are not a reliable indicator of these conditions

Conditions screened by Vistara may not be detected by ultrasound

ABILITY TO DETECT CONDITIONS WITH ULTRASOUND

A substantial number have no ultrasound findings

When there is no indication of a condition prenatally, clinicians and their patients cannot prepare for the birth of an affected child.

Many have late-gestation ultrasound findings

Ultrasound abnormalities for these conditions may present in the third trimester, when confirmatory invasive testing can pose a risk of preterm birth.

Many have non-specific ultrasound findings

Non-specific ultrasound findings, such as increased nuchal translucencies (NT) and heart defects, are relatively common and have a variety of genetic and non-genetic causes.

Conditions screened by Vistara may not be detected by ultrasound

ABILITY TO DETECT CONDITIONS WITH ULTRASOUND

A substantial number have no ultrasound findings

When there is no indication of a condition prenatally, clinicians and their patients cannot prepare for the birth of an affected child.

Many have late-gestation ultrasound findings

Ultrasound abnormalities for these conditions may present in the third trimester, when confirmatory invasive testing can pose a risk of preterm birth.

Many have non-specific ultrasound findings

Non-specific ultrasound findings, such as increased nuchal translucencies (NT) and heart defects, are relatively common and have a variety of genetic and non-genetic causes.

Conditions screened by Vistara may not be detected by ultrasound

ABILITY TO DETECT CONDITIONS WITH ULTRASOUND

A substantial number have no ultrasound findings

When there is no indication of a condition prenatally, clinicians and their patients cannot prepare for the birth of an affected child.

Many have late-gestation ultrasound findings

Ultrasound abnormalities for these conditions may present in the third trimester, when confirmatory invasive testing can pose a risk of preterm birth.

Many have non-specific ultrasound findings

Non-specific ultrasound findings, such as increased nuchal translucencies (NT) and heart defects, are relatively common and have a variety of genetic and non-genetic causes.

Conditions screened by Vistara may not be detected by ultrasound

ABILITY TO DETECT CONDITIONS WITH ULTRASOUND

A substantial number have no ultrasound findings

When there is no indication of a condition prenatally, clinicians and their patients cannot prepare for the birth of an affected child.

Many have late-gestation ultrasound findings

Ultrasound abnormalities for these conditions may present in the third trimester, when confirmatory invasive testing can pose a risk of preterm birth.

Many have non-specific ultrasound findings

Non-specific ultrasound findings, such as increased nuchal translucencies (NT) and heart defects, are relatively common and have a variety of genetic and non-genetic causes.

Screening with Vistara may help direct prenatal and neonatal care

Back to Top